1
|
Abstract
The kexin-like proprotein convertases perform the initial proteolytic cleavages that ultimately generate a variety of different mature peptide and proteins, ranging from brain neuropeptides to endocrine peptide hormones, to structural proteins, among others. In this review, we present a general introduction to proprotein convertase structure and biochemistry, followed by a comprehensive discussion of each member of the kexin-like subfamily of proprotein convertases. We summarize current knowledge of human proprotein convertase insufficiency syndromes, including genome-wide analyses of convertase polymorphisms, and compare these to convertase null and mutant mouse models. These mouse models have illuminated our understanding of the roles specific convertases play in human disease and have led to the identification of convertase-specific substrates; for example, the identification of procorin as a specific PACE4 substrate in the heart. We also discuss the limitations of mouse null models in interpreting human disease, such as differential precursor cleavage due to species-specific sequence differences, and the challenges presented by functional redundancy among convertases in attempting to assign specific cleavages and/or physiological roles. However, in most cases, knockout mouse models have added substantively both to our knowledge of diseases caused by human proprotein convertase insufficiency and to our appreciation of their normal physiological roles, as clearly seen in the case of the furin, proprotein convertase 1/3, and proprotein convertase 5/6 mouse models. The creation of more sophisticated mouse models with tissue- or temporally-restricted expression of specific convertases will improve our understanding of human proprotein convertase insufficiency and potentially provide support for the emerging concept of therapeutic inhibition of convertases.
Collapse
Affiliation(s)
- Manita Shakya
- Department of Anatomy and Neurobiology, University of Maryland School of Medicine, Baltimore, MD, USA
| | - Iris Lindberg
- Department of Anatomy and Neurobiology, University of Maryland School of Medicine, Baltimore, MD, USA
| |
Collapse
|
2
|
He J, Yang H, Xu Z, Li J, Chen G, Jiang L, Wu L, Zhou X. A functional polymorphism in the paired basic amino acid-cleaving enzyme 4 gene confers osteoarthritis risk in a population of Eastern China. Genet Mol Biol 2020; 43:e20190115. [PMID: 32167127 PMCID: PMC7197988 DOI: 10.1590/1678-4685-gmb-2019-0115] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/19/2019] [Accepted: 11/19/2019] [Indexed: 01/01/2023] Open
Abstract
Paired basic amino acid-cleaving enzyme 4 (PACE4), a proprotein convertase, is
involved in the activation of aggrecanases (ADAMTS-4 and ADAMTS-5) in
osteoarthritic and cytokine-stimulated cartilage. Activated aggrecanases cause
aggrecan degradation and thus, contribute to osteoarthritis (OA). In this study,
we investigated the association between PACE4 gene
polymorphisms and OA risk. One single-nucleotide polymorphism (rs4965833) in the
PACE4 gene was genotyped in 432 OA patients and 523 healthy
controls using matrix-assisted laser desorption/ionization time-of-flight mass
spectrometry. Quantitative reverse transcription PCR (qRT-PCR) was used to
determine the relative expression of PACE4 in blood samples
from 90 OA patients (30 for each genotype). The relative expression level of
PACE4 mRNA was higher in the GG genotype as compared to the
AA/AG group. Moreover, the PACE4 rs4965833 polymorphism was
associated with increased risk of OA, especially among individuals aged ≥55
years and with a body mass index ≥25. There was no significant association
between the PACE4 rs4965833 polymorphism and clinical
parameters of OA patients, such as erythrocyte sedimentation rate, C-reactive
protein, Visual Analog Scale for pain and Lequesne’s index. In conclusion, the
rs4965833 polymorphism in the 3’-UTR of PACE4 is associated
with OA susceptibility.
Collapse
Affiliation(s)
- Jin He
- Department of Orthopedics, Jintan Hospital Affiliated to Jiangsu University, Changzhou, China
| | - Haoyu Yang
- Department of Orthopedics, Wuxi No.9 People's Hospital Affiliated to Soochow University, Wuxi, Jiangsu, China
| | - Zhonghua Xu
- Department of Orthopedics, Jintan Hospital Affiliated to Jiangsu University, Changzhou, China
| | - Jin Li
- Department of Orthopedic Surgery, the Second Affiliated Hospital of Jiaxing University, Jiaxing, China
| | - Gang Chen
- Department of Orthopedic Surgery, the Second Affiliated Hospital of Jiaxing University, Jiaxing, China
| | - Lifeng Jiang
- Department of Orthopedic Surgery, The Second Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, China
| | - Lidong Wu
- Department of Orthopedic Surgery, The Second Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, China
| | - Xindie Zhou
- Department of Orthopedics, The Affiliated Changzhou No.2 People's Hospital of Nanjing Medical University, Changzhou, China
| |
Collapse
|
3
|
Cabanas-Danés J, Landman E, Huskens J, Karperien M, Jonkheijm P. Hydrolytically Labile Linkers Regulate Release and Activity of Human Bone Morphogenetic Protein-6. LANGMUIR : THE ACS JOURNAL OF SURFACES AND COLLOIDS 2018; 34:9298-9306. [PMID: 30005569 PMCID: PMC6143286 DOI: 10.1021/acs.langmuir.8b00853] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Figures] [Subscribe] [Scholar Register] [Received: 03/15/2018] [Revised: 05/24/2018] [Indexed: 06/08/2023]
Abstract
Release of growth factors while simultaneously maintaining their full biological activity over a period of days to weeks is an important issue in controlled drug delivery and in tissue engineering. In addition, the selected strategy to immobilize growth factors largely determines their biological activity. Silica surfaces derivatized with glycidyloxy propyl trimethoxysilane and poly(glycidyl methacrylate) brushes yielded epoxide-functionalized surfaces onto which human bone morphogenetic protein-6 (hBMP-6) was immobilized giving stable secondary amine bonds. The biological activity of hBMP-6 was unleashed by hydrolysis of the surface siloxane and ester bonds. We demonstrate that this type of labile bonding strategy can be applied to biomaterial surfaces with relatively simple and biocompatible chemistry, such as siloxane, ester, and imine bonds. Our data indicates that the use of differential hydrolytically labile linkers is a versatile method for functionalization of biomaterials with a variety of growth factors providing control over their biological activity.
Collapse
Affiliation(s)
- Jordi Cabanas-Danés
- Bioinspired
Molecular Engineering Laboratory, TechMed Centre, University of Twente, P.O. Box 217, 7500 AE Enschede, The Netherlands
- Molecular
Nanofabrication Group, MESA+ Institute for Nanotechnology, University of Twente,
P.O. Box 217, 7500 AE Enschede, The Netherlands
| | - Ellie Landman
- Developmental
BioEngineering Group, TechMed Centre, University
of Twente, P.O. Box 217, 7500 AE Enschede, The Netherlands
| | - Jurriaan Huskens
- Molecular
Nanofabrication Group, MESA+ Institute for Nanotechnology, University of Twente,
P.O. Box 217, 7500 AE Enschede, The Netherlands
| | - Marcel Karperien
- Developmental
BioEngineering Group, TechMed Centre, University
of Twente, P.O. Box 217, 7500 AE Enschede, The Netherlands
| | - Pascal Jonkheijm
- Bioinspired
Molecular Engineering Laboratory, TechMed Centre, University of Twente, P.O. Box 217, 7500 AE Enschede, The Netherlands
- Molecular
Nanofabrication Group, MESA+ Institute for Nanotechnology, University of Twente,
P.O. Box 217, 7500 AE Enschede, The Netherlands
| |
Collapse
|
4
|
Piubelli C, Castagna A, Marchi G, Rizzi M, Busti F, Badar S, Marchetti M, De Gobbi M, Roetto A, Xumerle L, Suku E, Giorgetti A, Delledonne M, Olivieri O, Girelli D. Identification of new BMP6 pro-peptide mutations in patients with iron overload. Am J Hematol 2017; 92:562-568. [PMID: 28335084 DOI: 10.1002/ajh.24730] [Citation(s) in RCA: 33] [Impact Index Per Article: 4.7] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/13/2016] [Revised: 02/09/2017] [Accepted: 03/18/2017] [Indexed: 12/16/2022]
Abstract
Hereditary Hemochromatosis (HH) is a genetically heterogeneous disorder caused by mutations in at least five different genes (HFE, HJV, TFR2, SLC40A1, HAMP) involved in the production or activity of the liver hormone hepcidin, a key regulator of systemic iron homeostasis. Nevertheless, patients with an HH-like phenotype that remains completely/partially unexplained despite extensive sequencing of known genes are not infrequently seen at referral centers, suggesting a role of still unknown genetic factors. A compelling candidate is Bone Morphogenetic Protein 6 (BMP6), which acts as a major activator of the BMP-SMAD signaling pathway, ultimately leading to the upregulation of hepcidin gene transcription. A recent seminal study by French authors has described three heterozygous missense mutations in BMP6 associated with mild to moderate late-onset iron overload (IO). Using an updated next-generation sequencing (NGS)-based genetic test in IO patients negative for the classical HFE p.Cys282Tyr mutation, we found three BMP6 heterozygous missense mutations in four patients from three different families. One mutation (p.Leu96Pro) has already been described and proven to be functional. The other two (p.Glu112Gln, p.Arg257His) were novel, and both were located in the pro-peptide domain known to be crucial for appropriate BMP6 processing and secretion. In silico modeling also showed results consistent with their pathogenetic role. The patients' clinical phenotypes were similar to that of other patients with BMP6-related IO recently described. Our results independently add further evidence to the role of BMP6 mutations as likely contributing factors to late-onset moderate IO unrelated to mutations in the established five HH genes.
Collapse
Affiliation(s)
- Chiara Piubelli
- Department of Medicine; Section of Internal Medicine, University of Verona, Verona, Italy; Veneto Region Referral Center for Iron Disorders, Azienda Ospedaliera Universitaria Integrata di Verona; Verona Italy
| | - Annalisa Castagna
- Department of Medicine; Section of Internal Medicine, University of Verona, Verona, Italy; Veneto Region Referral Center for Iron Disorders, Azienda Ospedaliera Universitaria Integrata di Verona; Verona Italy
| | - Giacomo Marchi
- Department of Medicine; Section of Internal Medicine, University of Verona, Verona, Italy; Veneto Region Referral Center for Iron Disorders, Azienda Ospedaliera Universitaria Integrata di Verona; Verona Italy
| | - Monica Rizzi
- Department of Medicine; Section of Internal Medicine, University of Verona, Verona, Italy; Veneto Region Referral Center for Iron Disorders, Azienda Ospedaliera Universitaria Integrata di Verona; Verona Italy
| | - Fabiana Busti
- Department of Medicine; Section of Internal Medicine, University of Verona, Verona, Italy; Veneto Region Referral Center for Iron Disorders, Azienda Ospedaliera Universitaria Integrata di Verona; Verona Italy
| | - Sadaf Badar
- Department of Medicine; Section of Internal Medicine, University of Verona, Verona, Italy; Veneto Region Referral Center for Iron Disorders, Azienda Ospedaliera Universitaria Integrata di Verona; Verona Italy
| | - Monia Marchetti
- Hematology section, Oncology Unit; Azienda Sanitaria Locale, Ospedale “Cardinal Massaia”; Asti Italy
| | - Marco De Gobbi
- Department of Clinical and Biological Sciences; University of Turin, Azienda Ospedaliera Universitaria San Luigi Gonzaga; Orbassano Turin Italy
| | - Antonella Roetto
- Department of Clinical and Biological Sciences; University of Turin, Azienda Ospedaliera Universitaria San Luigi Gonzaga; Orbassano Turin Italy
| | - Luciano Xumerle
- Department of Biotechnology; University of Verona; Verona Italy
| | - Eda Suku
- Department of Biotechnology; University of Verona; Verona Italy
| | | | | | - Oliviero Olivieri
- Department of Medicine; Section of Internal Medicine, University of Verona, Verona, Italy; Veneto Region Referral Center for Iron Disorders, Azienda Ospedaliera Universitaria Integrata di Verona; Verona Italy
| | - Domenico Girelli
- Department of Medicine; Section of Internal Medicine, University of Verona, Verona, Italy; Veneto Region Referral Center for Iron Disorders, Azienda Ospedaliera Universitaria Integrata di Verona; Verona Italy
| |
Collapse
|
5
|
Guillemot J, Seidah NG. PACE4 (PCSK6): another proprotein convertase link to iron homeostasis? Haematologica 2016; 100:e377. [PMID: 26341526 DOI: 10.3324/haematol.2015.127175] [Citation(s) in RCA: 5] [Impact Index Per Article: 0.6] [Reference Citation Analysis] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/11/2023] Open
Affiliation(s)
- Johann Guillemot
- Laboratory of Biochemical Neuroendocrinology, Clinical Research Institute of Montreal (IRCM), affiliated to the University of Montreal, Montreal, Quebec, H2W 1R7, Canada
| | - Nabil G Seidah
- Laboratory of Biochemical Neuroendocrinology, Clinical Research Institute of Montreal (IRCM), affiliated to the University of Montreal, Montreal, Quebec, H2W 1R7, Canada
| |
Collapse
|
6
|
Kleven MD, Enns CA, Zhang AS. Bone Morphogenetic Protein-6 Mutations Take Their Place in Iron Overload Diseases. Gastroenterology 2016; 150:556-9. [PMID: 26820052 DOI: 10.1053/j.gastro.2016.01.016] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 02/08/2023]
Affiliation(s)
- Mark D Kleven
- Department of Cell, Developmental and Cancer Biology, Oregon Health & Science University, Portland, Oregon
| | - Caroline A Enns
- Department of Cell, Developmental and Cancer Biology, Oregon Health & Science University, Portland, Oregon.
| | - An-Sheng Zhang
- Department of Cell, Developmental and Cancer Biology, Oregon Health & Science University, Portland, Oregon
| |
Collapse
|
7
|
Couture F, Levesque C, Dumulon-Perreault V, Ait-Mohand S, D'Anjou F, Day R, Guérin B. PACE4-based molecular targeting of prostate cancer using an engineered ⁶⁴Cu-radiolabeled peptide inhibitor. Neoplasia 2015; 16:634-43. [PMID: 25220591 PMCID: PMC4235008 DOI: 10.1016/j.neo.2014.07.010] [Citation(s) in RCA: 10] [Impact Index Per Article: 1.1] [Reference Citation Analysis] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/02/2014] [Revised: 07/28/2014] [Accepted: 07/31/2014] [Indexed: 01/14/2023] Open
Abstract
The potential of PACE4 as a pharmacological target in prostate cancer has been demonstrated as this proprotein convertase is strongly overexpressed in human prostate cancer tissues and its inhibition, using molecular or pharmacological approaches, results in reduced cell proliferation and tumor progression in mouse tumor xenograft models. We developed a PACE4 high-affinity peptide inhibitor, namely, the multi-leucine (ML), and sought to determine whether this peptide could be exploited for the targeting of prostate cancer for diagnostic or molecular imaging purposes. We conjugated a bifunctional chelator 1,4,7-triazacyclononane-1,4,7- triacetic acid (NOTA) to the ML peptide for copper-64 ((64)Cu) labeling and positron emission tomography (PET)- based prostate cancer detection. Enzyme kinetic assays against recombinant PACE4 showed that the NOTA-modified ML peptide displays identical inhibitory properties compared to the unmodified peptide. In vivo biodistribution of the (64)Cu/NOTA-ML peptide evaluated in athymic nude mice bearing xenografts of two human prostate carcinoma cell lines showed a rapid and high uptake in PACE4-expressing LNCaP tumor at an early time point and in PACE4-rich organs. Co-injection of unlabeled peptide confirmed that tumor uptake was target-specific. PACE4-negative tumors displayed no tracer uptake 15 minutes after injection, while the kidneys, demonstrated high uptake due to rapid renal clearance of the peptide. The present study supports the feasibility of using a (64)Cu/NOTA-ML peptide for PACE4-targeted prostate cancer detection and PACE4 status determination by PET imaging but also provides evidence that ML inhibitor-based drugs would readily reach tumor sites under in vivo conditions for pharmacological intervention or targeted radiation therapy.
Collapse
Affiliation(s)
- Frédéric Couture
- Institut de Pharmacologie de Sherbrooke, Department of Surgery/Urology Division, Université de Sherbrooke, Sherbrooke, Québec, Canada
| | - Christine Levesque
- Institut de Pharmacologie de Sherbrooke, Department of Surgery/Urology Division, Université de Sherbrooke, Sherbrooke, Québec, Canada
| | - Véronique Dumulon-Perreault
- Centre de Recherche Clinique Étienne-Le Bel, Department of Nuclear Medicine and Radiobiology, Université de Sherbrooke, Sherbrooke, Québec, Canada
| | - Samia Ait-Mohand
- Centre de Recherche Clinique Étienne-Le Bel, Department of Nuclear Medicine and Radiobiology, Université de Sherbrooke, Sherbrooke, Québec, Canada
| | - François D'Anjou
- Institut de Pharmacologie de Sherbrooke, Department of Surgery/Urology Division, Université de Sherbrooke, Sherbrooke, Québec, Canada
| | - Robert Day
- Institut de Pharmacologie de Sherbrooke, Department of Surgery/Urology Division, Université de Sherbrooke, Sherbrooke, Québec, Canada.
| | - Brigitte Guérin
- Centre de Recherche Clinique Étienne-Le Bel, Department of Nuclear Medicine and Radiobiology, Université de Sherbrooke, Sherbrooke, Québec, Canada.
| |
Collapse
|
8
|
Lin YE, Wu QN, Lin XD, Li GQ, Zhang YJ. Expression of paired basic amino acid-cleaving enzyme 4 (PACE4) correlated with prognosis in non-small cell lung cancer (NSCLC) patients. J Thorac Dis 2015; 7:850-60. [PMID: 26101640 DOI: 10.3978/j.issn.2072-1439.2015.05.09] [Citation(s) in RCA: 8] [Impact Index Per Article: 0.9] [Reference Citation Analysis] [Abstract] [Key Words] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/07/2015] [Accepted: 05/11/2015] [Indexed: 12/27/2022]
Abstract
BACKGROUND Paired basic amino acid-cleaving enzyme 4 (PACE4) was shown to enhance tumor cells proliferation and invasive. This study provides the first investigation of PACE4 expression in non-small cell lung cancer (NSCLC) and the correlation with clinicopathologic features, prognostic indicators of 172 cases. METHODS Quantitative real-time PCR (RT-PCR) and immunofluorescence (IF) were applied to detect PACE4 expression in NSCLC and 16HBE cell lines, then 172 consecutive NSCLC and 15 normal lung tissues were studied through immunohistochemistry (IHC). The association between PACE4 expression and clinicopathological parameters was evaluated. Kaplan-Meier survival analysis and Cox proportional hazards models were used to estimate the effect of PACE4 expression on survival. RESULTS PACE4 expression in NSCLC were significantly higher than normal lung cell and tissues (P<0.05). PACE4 had cytoplasmic expression and was observed in 111 of the 172 (64.5%) NSCLC patients. Clinicopathologically, PACE4 expression was significantly associated with lymph node metastasis (N stage) (P=0.007), and clinical stage (P=0.024). Multivariable analysis confirmed that PACE4 expression increased the hazard of death after adjusting for other clinicopathological factors [hazards ratio (HR): 1.584; 95% confidence interval (CI): 1.167-2.151; P<0.001]. Overall survival (OS) was significantly prolonged in PACE4 negative group when compared with PACE4 positive group (5-year survival rates, 23.1% vs. 54.5%, log-rank test, χ(2)=17.717, P<0.001), as was disease-free survival (DFS) (5-year survival rates, 23.4% vs. 55.4%, log-rank test, χ(2)=20.486, P<0.001). CONCLUSIONS Our results suggest that positive expression of PACE4 is an independent factor for NSCLC patients and it might serve as a potential prognostic biomarker for patients with NSCLC.
Collapse
Affiliation(s)
- Yun-En Lin
- 1 Department of Pathology, Guangzhou Medical University, Guangzhou 510182, China ; 2 Department of Pathology, The First Affiliated Hospital of Guangzhou Medical University, Guangzhou 510120, China
| | - Qi-Nian Wu
- 1 Department of Pathology, Guangzhou Medical University, Guangzhou 510182, China ; 2 Department of Pathology, The First Affiliated Hospital of Guangzhou Medical University, Guangzhou 510120, China
| | - Xiao-Dong Lin
- 1 Department of Pathology, Guangzhou Medical University, Guangzhou 510182, China ; 2 Department of Pathology, The First Affiliated Hospital of Guangzhou Medical University, Guangzhou 510120, China
| | - Guang-Qiu Li
- 1 Department of Pathology, Guangzhou Medical University, Guangzhou 510182, China ; 2 Department of Pathology, The First Affiliated Hospital of Guangzhou Medical University, Guangzhou 510120, China
| | - Ya-Jie Zhang
- 1 Department of Pathology, Guangzhou Medical University, Guangzhou 510182, China ; 2 Department of Pathology, The First Affiliated Hospital of Guangzhou Medical University, Guangzhou 510120, China
| |
Collapse
|
9
|
Kim H, Tabata A, Tomoyasu T, Ueno T, Uchiyama S, Yuasa K, Tsuji A, Nagamune H. Estrogen stimuli promote osteoblastic differentiation via the subtilisin-like proprotein convertase PACE4 in MC3T3-E1 cells. J Bone Miner Metab 2015; 33:30-9. [PMID: 24557631 DOI: 10.1007/s00774-014-0567-9] [Citation(s) in RCA: 13] [Impact Index Per Article: 1.4] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 08/20/2013] [Accepted: 01/06/2014] [Indexed: 10/25/2022]
Abstract
Estrogenic compounds include endogenous estrogens such as estradiol as well as soybean isoflavones, such as daidzein and its metabolite equol, which are known phytoestrogens that prevent osteoporosis in postmenopausal women. Indeed, mineralization of MC3T3-E1 cells, a murine osteoblastic cell line, was significantly decreased in medium containing fetal bovine serum treated with charcoal-dextran to deplete endogenous estrogens, but estradiol and these soybean isoflavones dose-dependently restored the differentiation of MC3T3-E1 cells; equol was tenfold more effective than daidzein. These differentiation-promoting effects were inhibited by the addition of fulvestrant, which is a selective downregulator of estrogen receptors. Analysis of the expression pattern of bone-related genes by reverse transcription PCR (RT-PCR)/quantitative real-time PCR (qRT-PCR), which focused on responsiveness to the estrogen stimuli, revealed that the transcription of PACE4, a subtilisin-like proprotein convertase, was tightly linked with the differentiation of MC3T3-E1 cells induced by estrogen stimuli. Moreover, treatment with RNAi of PACE4 in MC3T3-E1 cells resulted in a drastic decrease of mineralization in the presence of estrogen stimuli. These results strongly suggest that PACE4 participates in bone formation at least in osteoblast differentiation, and estrogen receptor-mediated stimuli induce osteoblast differentiation through the upregulation of PACE4 expression.
Collapse
Affiliation(s)
- Hyejin Kim
- Department of Biological Science and Technology, Institute of Technology and Science, The University of Tokushima Graduate School, #2-1, Minami-josanjima, Tokushima, 770-8506, Japan
| | | | | | | | | | | | | | | |
Collapse
|